We also identify distinct cellular and molecular signatures of responders and nonresponders that are unique to treatment with combined TGFβ inhibition and PD-L1 blockade, and demonstrate their requirement for a successful anti-tumor response to bintrafusp alfa. This evidence concerns the gene CD274 and neoplasm.